Vanderson Rocha, Jarl E Mooyaart, Ron Ram, Katherine Clesham, Michael Daskalakis, Anne Huynh, Victoria Potter, Sridhar Chaganti, Ludovic Gabellier, Eleni Tholouli, Matthew Collin, Emma Nicholson, Rachel Protheroe, Jacob Passweg, Francis Ayuk, Dominik Schneidawind, Mi Kwon, Lucia Lopez Corral, Robert Zeiser, Christof Scheid, Ibrahim Yakoub-Agha, Peter Dreger, Friedrich Stolzel, Jorinde Hoogenboom, Maiana Hamdan Melo Coelho, Ana Alarcon Tomas, Florent Malard, Jürgen Kuball, Anna Sureda, Ali Barzabachi, Annalisa Ruggeri
Chimeric antigen receptor(CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma(LBCL), but evidence in elderly patients(≥70y) is limited. We compared outcomes of tisagenlecleucel(tisa-cel) and axicabtagene ciloleucel(axi-cel) and assessed prognostic factors. We analyzed 1,191 patients(aged ≥70y) reported to the EBMT(tisa-cel n=402; axi-cel n=789). Median follow-up was 22.7 months. Outcomes included cytokine release syndrome(CRS), immune effector cell-associated neurotoxicity syndrome(ICANS), overall survival(OS), progression-free survival(PFS), relapse incidence(RI), and non-relapse mortality(NRM). Multivariable models adjusted for age, sex, ECOG, disease status, prior transplantation, and year of infusion. Median age at infusion was 74y; 65.6% were aged 70-75y. Progressive disease at infusion was 59% vs 53% for tisa-cel and axi-cel(p=0.04). Tisa-cel patients were older(74.0 vs 73.7y, p=0.019). At day-30, CRS(any grade) occurred in 62% vs 77%(p.